Vaughan Nelson Investment Management L.P. Has $30.64 Million Stock Position in Avantor, Inc. (NYSE:AVTR)

Vaughan Nelson Investment Management L.P. lowered its stake in Avantor, Inc. (NYSE:AVTR) by 52.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,198,359 shares of the company’s stock after selling 1,310,198 shares during the quarter. Vaughan Nelson Investment Management L.P. owned about 0.18% of Avantor worth $30,642,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Fifth Third Bancorp raised its stake in Avantor by 125.3% during the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock worth $28,000 after buying an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its stake in Avantor by 565.5% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after buying an additional 1,131 shares during the period. Gladius Capital Management LP acquired a new stake in Avantor during the 4th quarter worth $42,000. Montag A & Associates Inc. acquired a new stake in Avantor during the 4th quarter worth $43,000. Finally, TFO Wealth Partners LLC raised its stake in Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after buying an additional 2,031 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on AVTR. Evercore ISI dropped their price objective on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday. Deutsche Bank Aktiengesellschaft increased their target price on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Thursday, April 18th. Barclays lowered their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Finally, Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, April 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $26.29.

Avantor Price Performance

Shares of NYSE AVTR opened at $20.58 on Wednesday. Avantor, Inc. has a fifty-two week low of $16.63 and a fifty-two week high of $26.16. The stock has a market capitalization of $13.98 billion, a price-to-earnings ratio of 52.77, a PEG ratio of 2.15 and a beta of 1.32. The business has a 50-day moving average of $23.66 and a 200-day moving average of $23.81. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.61 and a quick ratio of 1.05.

Avantor (NYSE:AVTR) last issued its earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same period last year, the business posted $0.29 EPS. Avantor’s revenue was down 5.6% on a year-over-year basis. As a group, sell-side analysts predict that Avantor, Inc. will post 1.01 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.